CBD Broad Spectrum & Novel Foods, January Application Confirmed
In another year of surging demand, CBD products have been undergoing increased testing in the anticipation of the instilment of Novel Foods. This has been something we have been taking extremely seriously since the EU & UK FSA announcement in March.
The vast majority of companies in the UK and EU that are making Novel Foods submissions are currently only including isolate CBD in their applications, this is largely due to it being easier and cheaper to put through the extensive and expensive process of testing involved in a Novel Foods submission. Whilst isolate CBD is great in many applications, isolate based products are by their nature, only focused on CBD and miss some of the more delicate but equally important benefits of having a wider range of cannabinoids. You may well know it as the ‘entourage effect’ described in many cases regarding full spectrum and broad spectrum products.
Apex White Label and our supporting partners have been underway with a Novel Foods submission for our full range of broad spectrum products to ensure our current crop of white label CBD clients can access the market without hinderance as of the 31st of March 2021. This will also pave the way for exciting new opportunities within the CBD space utilising our soon to be accredited product lines.
This is without doubt the largest shift in regulatory compliance that the CBD industry has ever seen and we have been working hard to ensure we are at the forefront of the shift, keeping up with all aspects of the ever changing landscape with this and the impending UK exit of the European Union.
All brands working with Apex White Label will be contacted this week to ensure smooth passage into the new era of regulation, keep an eye out for emails incoming in the next few days.
If you’re unsure whether your current supply chain will be compliant with the incoming legislation, please feel free to reach out for a no obligation discussion with our team.